The global cystic fibrosis therapeutics market is expected to reach USD 13.9 billion by 2025, according to a new report by Grand View Research, Inc. The rising prevalence of Cystic Fibrosis (CF) globally, research & development activities undertaken by key players, and favorable initiatives undertaken by nonprofit organizations are expected to boost the market over the forecast period.
The
rising prevalence of CF indicates the rising demand for treatment alternatives,
thereby uplifting the market. The key players operating in this market in
collaboration with nonprofit organizations focus on the development of novel
therapeutics for treatment. Some of the drugs that are under clinical studies
are VX-445 + tezacaftor + ivacaftor, PTI-428, QR-010, AZD5634, and POL6014.
Favorable
initiatives taken by regional and national nonprofit organizations is one of
the key factors propelling growth. These initiatives ensure support to CF
patients. These organizations aid in research & development activities of
these therapeutics and help improve the quality of life of these patients. For
instance, North American Cystic Fibrosis Conference (NACFC) was formed in 1986
to provide a collaborative and educational forum to CF professionals to share
advances in R&D related to CF therapeutics.
Full Research Report On Cystic Fibrosis Therapeutics Market Visit Here:
https://www.grandviewresearch.com/industry-analysis/cystic-fibrosis-cf-therapeutics-market
Further key
findings from the report suggest:
- The global CF therapeutics
market size was estimated at USD 3,560.5 million in 2016 and is expected
to grow at a CAGR of 16.7% from 2017 to 2025
- The CFTR modulator segment
emerged as the largest segment in 2016 and the same segment is anticipated
to witness fastest growth over the next 8 years owing to the approval of
CFTR modulator, Orkambi and the presence of various investigational
compounds under the pipeline.
- Oral route of administration
emerged as the largest segment with revenue of USD 2,266.4 million due to
the ease of administration and convenience
- North America accounted for
the largest market share owing to the presence of Caucasian descents in
this region. Improved healthcare infrastructure, reimbursements, and
initiatives undertaken by the nonprofit organizations is expected to
propel the market over forecast period,
- The key players include
AbbVie Inc., F. Hoffmann-La Roche Ltd.; Gilead, Novartis AG, Vertex
Pharmaceuticals Inc., AIT (Advanced Inhalation Therapies), Alaxia, Teva
Pharmaceutical Industries Ltd, Merck & Co. Inc., Alcresta Therapeutics
Inc., Allergan, and AstraZeneca
Request a Sample Copy of the Report @
https://www.grandviewresearch.com/industry-analysis/cystic-fibrosis-cf-therapeutics-market/request/rs1
Grand View Research has segmented
the cystic fibrosis therapeutics market on the basis of drug class, route of
administration and region:
Cystic Fibrosis
Therapeutics Drug Class Outlook (Revenue, USD Million, 2014 - 2025)
- Pancreatic enzyme
supplements
- Mucolytics
- Bronchodilators
- CFTR modulators
Cystic Fibrosis
Therapeutics Route of Administration Outlook (Revenue, USD Million, 2014 -
2025)
- Oral drugs
- Inhaled drugs
Cystic Fibrosis
Therapeutics Regional Outlook (Revenue, USD Million, 2014 - 2025)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia Pacific
- China
- Japan
- Latin America
- Brazil
- Mexico
- Middle East & Africa
- South Africa
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment